Urofollitropin is a purified form of follicle-stimulating hormone (FSH) commonly used in assisted reproductive technologies (ART) to promote follicular development in women undergoing fertility treatments such as in vitro fertilization (IVF). Administered via subcutaneous or intramuscular injections, its use is carefully monitored through ultrasound and serum estradiol levels to ensure an appropriate ovarian response and to adjust dosages as needed.
Current treatment guidelines suggest starting urofollitropin on the second or third day of the menstrual cycle with an initial dose of 225 units per day for the first five days. The dosage may be modified based on the ovarian response, with a maximum daily dose of 450 units. Treatment duration should not exceed 12 days.
There are important precautions and risks associated with urofollitropin. A key concern is ovarian hyperstimulation syndrome (OHSS), a potentially serious condition characterized by symptoms such as abdominal pain, bloating, and nausea. In severe cases, it can lead to complications like thromboembolism and respiratory issues. To minimize this risk, careful monitoring and dosage adjustments are essential. Patients with enlarged ovaries are advised to avoid strenuous physical activity and sexual intercourse.
Urofollitropin is contraindicated in women with certain medical conditions, including primary ovarian failure, unexplained vaginal bleeding, reproductive organ tumors, and known hypersensitivity to the drug. It is not recommended for use during pregnancy due to potential risks to the fetus, and breastfeeding mothers are advised against its use.
For proper storage, urofollitropin should be kept at room temperature or refrigerated, protected from light, and used immediately after reconstitution. Any unused medication should be disposed of appropriately.
Overall, urofollitropin plays a crucial role in fertility treatments, but its administration requires strict medical supervision to ensure safety and effectiveness. Regular monitoring and follow-ups with healthcare providers are essential to optimize treatment outcomes and manage potential side effects.
